David E. Lazar, Interim CEO at Cyclacel Pharmaceuticals, Inc. (CYCC), sold 389,257,640 shares at $0.03 ($11.7M) on 2025-02-26, disclosed to the SEC on 2025-02-28.
Open-market sale of $11.7M CYCC by Interim CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.03 | 194,628,820 | $5.8M | 50.0% |
| 2 | $0.03 | 194,628,820 | $5.8M | 50.0% |
| Total | $0.03 avg | 389,257,640 | $11.7M | 100% |
| Filing → |
| TTNP | BUY | 2022-07-08 | $3.8M | — | Filing → |